Business
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne are the two most commonly diagnosed skin disorders in the US1 WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announ
About this update from Biofrontera Inc.
[{"type":"image","alt":"Biofrontera Inc.","displaySize":"","headline":null,"caption":"Biofrontera Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bVH36b1WxYUx1e199mXo7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Data generated will support key regulatory milestones for Ameluz PDT in both indications","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"AK and acne are the two most commonly diagnosed skin disorders in the US1","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":259,"olType":false},{"type":"text","content":"WOBURN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database lock of two clinical studies evaluating Ameluz® PDT, marking an important milestone ahead of several anticipated data and regulatory events in 2026.","length":416,"tagName":"p"},{"type":"text","content":"The databases for the treatment phase of the Company’s Phase 3 clinical study evaluating Ameluz® PDT for the treatment of actinic keratosis (AK) on the extremities, neck and trunk as well as its Phase 2 clinical study evaluating the treatment of moderate to severe acne vulgaris were successfully locked on January 5, 2026.","length":323,"tagName":"p"},{"type":"text","content":"All data from participants that is collected throughout each study is captured in a specific database. Locking the database enables unblinding and statistical analysis of the study results in accordance with the pre-specified study endpoints. Biofrontera expects data for both studies to be available in February of this year.","length":326,"tagName":"p"},{"type":"text","content":"Actinic keratosis and acne vulgaris are the two skin disorders most co...